Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer.
Patell K, Mears VL, Storandt MH, Mahipal A.
Expert Opin Drug Metab Toxicol · review; journal article · DOI 10.1080/17425255.2024.2332364 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för fruquintinib. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
39 hitsExtended survival with metastatic pancreatic cancer under fruquintinib treatment after failed chemotherapy: Two case reports.
Wu D, Wang Q, Yan S, Sun X, Qin Y, Yuan M, Wang NY, Huang XT.
World J Clin Cases · journal article; case reports; case-report · DOI 10.12998/wjcc.v12.i7.1296Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
Stucchi E, Bartolini M, Airoldi M, Fazio R, Daprà V, Mondello G, Prete MG, Puccini A, Santoro A.
Expert Opin Pharmacother · review; journal article · DOI 10.1080/14656566.2024.2336069Fruquintinib (Fruzaqla) for metastatic colorectal cancer.
Författaruppgift saknas
Med Lett Drugs Ther · journal article · DOI 10.58347/tml.2024.1696fFruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol.
Wu L, Yan H, Qin Y, Huang M, Wang T, Jin Q, Wei W.
BMJ Open · clinical trial protocol; research support, non-u.s. gov't; research-article; journal article · DOI 10.1136/bmjopen-2023-075696Significant response from fruquintinib plus anti-PD-1 immunotherapy for microsatellite stable metastatic colorectal cancer with liver and lung metastasis in the third line: case report.
He L, Cheng X, Zhou C, Li Q, Zhang B, Cheng X, Donadon M, Mannavola F, Tu S.
J Gastrointest Oncol · journal article; case reports; case-report · DOI 10.21037/jgo-23-862Efficacy, safety, and predictors of fruquintinib plus anti-programmed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study.
Yang X, Yin X, Qu X, Guo G, Zeng Y, Liu W, Jagielski M, Liu Z, Zhou H.
J Gastrointest Oncol · research-article; journal article · DOI 10.21037/jgo-23-931A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer.
Zou J, Wang Y, Xu J, Li J, Wang T, Zhang Y, Bai Y.
J Clin Med · research-article; journal article · DOI 10.3390/jcm13010057Toripalimab and fruquintinib therapy for colorectal cancer after failed multiline chemotherapies: a case report.
Kong LZ, Zheng Y, Li K.
Immunotherapy · journal article; case reports · DOI 10.2217/imt-2023-0235Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study.
Tan S, Zhang S, Zhou N, Cai X, Yi C, Gou H.
Cancer Med · clinical trial, phase ii; research-article; multicenter study; journal article · DOI 10.1002/cam4.6786Fruquintinib
Författaruppgift saknas
Journal missing · reviewFecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215).
Zhao W, Lei J, Ke S, Chen Y, Xiao J, Tang Z, Wang L, Ren Y, Alnaggar M, Qiu H, Shi W, Yin L, Chen Y.
EClinicalMedicine · research-article; journal article · DOI 10.1016/j.eclinm.2023.102315Fruquintinib in combination with sintilimab or TAS-102 as third-line or above treatment in patients with metastatic colorectal cancer: a real-world study.
Li L, Wang T, Wu Z, Li Y, Ma H, Wang L, Lei S, Chen W.
Transl Cancer Res · research-article; journal article · DOI 10.21037/tcr-23-867RIFLE: a Phase II trial of stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer.
Wang K, Chen Y, Zhang Z, Wu R, Zhou M, Yang W, Wan J, Shen L, Zhang H, Wang Y, Han X, Wang J, Zhang Z, Xia F.
Gastroenterol Rep (Oxf) · research-article; journal article · DOI 10.1093/gastro/goad063Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States.
Wang-Gillam A, Schelman W, Ukrainskyj S, Chien C, Gonzalez M, Yang Z, Kania M, Yeckes-Rodin H.
Invest New Drugs · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s10637-023-01395-yDesign, synthesis and biological evaluation of VEGFR-2/HDAC dual inhibitors as multitargeted antitumor agents based on fruquintinib and vorinostat.
Gao Y, Li F, Ni X, Yang S, Liu H, Wu X, Liu J, Ma J.
RSC Adv · research-article; journal article · DOI 10.1039/d3ra05542fCase report: PRES associated with fruquintinib in a patient with metastatic colon cancer.
Wang L, Zeng Z, Wu Z.
Neurol Sci · brief-report; journal article; case reports · DOI 10.1007/s10072-023-06991-7Anlotinib and fruquintinib co-administrated with warfarin increases the risk of bleeding: Studied from pharmacokinetic and pharmacodynamic perspectives.
Fang B, Jin S, Du W, Cai W.
Eur J Pharm Sci · journal article · DOI 10.1016/j.ejps.2023.106507Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C, FRESCO-2 Study Investigators.
Lancet · clinical trial, phase iii; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(23)00772-9Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report.
Qu FJ, Wu S, Kong Y.
World J Gastrointest Oncol · journal article; case reports; case-report · DOI 10.4251/wjgo.v15.i5.902Durable responses to tislelizumab plus fruquintinib and radiotherapy in refractory microsatellite stable metastatic colorectal cancer: a case report.
Zhao W, Huang Z.
Am J Transl Res · journal article; case reports; case-reportDC101, an anti-VEGFR2 agent, promotes high-endothelial venule formation and immune infiltration versus SAR131675 and fruquintinib.
Wang Z, Shi X, Zhao Y, Zhou J, Zhang S, Wang J, Yu W, Zhang X, Ren X, Zhao H.
Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2023.04.018Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study.
Ding X, Liu Y, Zhang Y, Liang J, Li Q, Hu H, Zhou Y.
Anticancer Drugs · research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1097/cad.0000000000001482Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer.
Lavacchi D, Roviello G, Guidolin A, Romano S, Venturini J, Caliman E, Vannini A, Giommoni E, Pellegrini E, Brugia M, Pillozzi S, Antonuzzo L.
Int J Mol Sci · review-article; review; journal article · DOI 10.3390/ijms24065840Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
Deng YY, Zhang XY, Zhu PF, Lu HR, Liu Q, Pan SY, Chen ZL, Yang L.
Front Oncol · research-article; journal article · DOI 10.3389/fonc.2023.1097911Acute aortic dissection caused by fruquintinib for metastatic colorectal cancer-a case report and literature review.
Deng YY, Chen YW, Wang MX, Zhu PF, Pan SY, Jiang DY, Chen ZL, Yang L.
Transl Cancer Res · journal article; case reports; case-report · DOI 10.21037/tcr-22-1872Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer.
Nukatsuka M, Fujioka A, Nagase H, Tanaka G, Hayashi H.
Chemotherapy · research-article; journal article · DOI 10.1159/000528867Brief insight into the in silico properties, structure-activity relationships and biotransformation of fruquintinib, an anticancer drug of a new generation containing a privileged benzofuran scaffold.
Nádaská D, Hudecova L, Kováč G, Malík I.
Ceska Slov Farm · review; journal article · DOI 10.5817/csf2023-6-267Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.
Guo Y, Zhang W, Ying J, Zhang Y, Pan Y, Qiu W, Fan Q, Xu Q, Ma Y, Wang G, Guo J, Su W, Fan S, Tan P, Wang Y, Luo Y, Zhou H, Li J.
Eur J Cancer · clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1016/j.ejca.2022.12.004Fruquintinib/HMPL-013 ameliorates cognitive impairments and pathology in a mouse model of cerebral amyloid angiopathy (CAA).
Zhou G, Xiang T, Xu Y, He B, Wu L, Zhu G, Xie J, Yao L, Xiao Z.
Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2022.175446